Search results
Added:
1 week ago
Source:
Radcliffe Cardiology
The first month following primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is a period of high risk for major adverse cardiovascular events (MACEs). The TADCLOT trial aimed to compare the efficacy of ticagrelor against a twice-daily clopidogrel regimen in this critical short-term window.¹The TADCLOT (Twice-A-Day CLOpidogrel vs Ticagrelor)…
View more
Author(s):
Joo-Yong Hahn
Added:
8 months ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel…
View more
Author(s):
Paul Haller
,
Benedikt Schrage
Added:
1 year ago
Author(s):
Robert F Storey
Added:
1 year ago
Author(s):
Kevin S Tang
,
Shoujit Banerjee
,
George Tang
,
et al
Added:
2 years ago
Author(s):
Duy Cao Phuong Le
,
Hoa The Bui
,
Quan Duy Vo
Added:
1 year ago
Konstantinos C Siontis
Job title: Cardiac Electrophysiologist, Assistant Professor of Medicine
Author
Keith AA Fox
Research Area(s) / Expertise:
Job title: Professor
Author
Author(s):
Bobbi Bogaev Chapman
,
Manreet Kanwar
,
Jane Wilcox
,
et al
Added:
1 year ago
Author(s):
Andrea M Steely
Added:
1 month ago
Navigate the evolving landscape of surgical coronary revascularization with Dr Andrea SteelyThis presentation, part of the Complex Cases track in Women As One's CLIMB® 2025 Skills Training Program, provides a comprehensive overview of traditional and contemporary approaches to treating coronary artery disease.Dr Steely examines traditional coronary artery bypass grafting (CABG) alongside…
View more